CONCLUSIONS: Significant treatment effects of 15-mg AMG 747, but not higher or lower doses, were observed on secondary endpoints but not on the primary outcome. These results replicate previous reports of an inverted-U dose response curve and suggest further evaluation of GlyT1 inhibitors in schizophrenia negative symptoms is warranted.
1 Like
Is this something like sarcosine? I know “glycine” has something to do with sarcosine. Maybe this drug works similarly to sarcosine?
Seems like there’s a move to resurrect something that was terminated.
Yes - same brain receptor target as sarcosine, and other medications that have been in development.
Here is a longer list of all the medications that are or have been in development, and sarcosine - that target this receptor:
http://www.nature.com/nrd/journal/v12/n11/fig_tab/nrd3893_T1.html
1 Like
Are these drugs good for both positive and negative symptoms or strictly used as add ins to current antipsychotic therapy ?
All the research I’ve seen suggests they are complimentary to current antipsychotic therapy - and focused on negative symptoms.
1 Like
Do you know what the safety issues were with AMG747 that resulted in termination?
Also, any idea how far off these types of medications are from being released to the public?
I really wish bitopertin had of made it to market i dont really see how sarcosine can help but yet bitopertin didnt 
1 Like
isn’t that one available in Japan only or maybe that blonoserin?
i dont think its available anywhere
They are different molecules, but similar. Just because one works doesn’t mean another does or does not work. There are many instances of situations where one molecule in a given family (meaning they are similar chemically) may work and another does not work in people. Also - different molecules may have different impacts on different people - so each may be helping different, and different percentages, of people who use them.
1 Like